publication date: Jun. 5, 2020

NCI Trials

NCI Trials for June 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – NRG-GI007

Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery

NRG Oncology

Ku, Geoffrey Yuyat

(646) 888-4588

 

Phase I/II – 10313

A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology

University of Pittsburgh Cancer Institute LAO

Villaruz, Liza C.

(412) 648-6577

 

Phase II – 10300

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia

Yale University Cancer Center LAO

Zeidan, Amer M.

(203) 737-2572

 

Phase II – APEC1621M

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations

Children’s Oncology Group

Pratilas, Christine Anne

(443) 287-8623

 

Phase II – EA5191

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

ECOG-ACRIN Cancer Research Group

Neal, Joel William

(650) 725-3081

 

Phase II – TRC-10446

Tocilizumab in Hospitalized Cancer Patients with Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)

National Cancer Institute

Little, Richard Fowler

(240) 276-6560

 

Phase III – A081801

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Alliance for Clinical Trials in Oncology

Sands, Jacob M.

(671) 632-6049

 

Phase III – NRG-CC005

FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

NRG Oncology

Schoen, Robert E.

(412) 648-9825

 

Phase III – S1925

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

SWOG

Stephens, Deborah Marie

(801) 587-4354

 

Phase III – WF-1901

Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

Wake Forest NCORP Research Base

Penzien, Donald B.

(336) 716-4382

 

Phase Other – NCICOVID

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

National Cancer Institute

Korde, Larissa A.

(240) 276-6077

Copyright (c) 2020 The Cancer Letter Inc.